Respiratory medicine · 2026
Effects of integrated inspiratory-expiratory muscle training within hybrid cardiac rehabilitation following cardiac surgery: A randomized controlled study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eksi Busra Ulker, Cilbir Cigdem Emirza, Ucgun Hikmet, Ertan Harputlu Ozge, Aslan Goksen Kuran, Ezelsoy Mehmet, Ugurlucan Murat, Sagbas Liva Ertan, Akinci Buket
Аннотация
BACKGROUND: Cardiac surgery may reduce pulmonary function, respiratory muscle strength, and functional capacity after surgery. Respiratory muscle training (RMT) is recommended in cardiac rehabilitation; however, evidence regarding RMT within HCR remains limited.
OBJECTIVE: To evaluate the effects of adding RMT to an HCR program following cardiac surgery in a randomized controlled trial.
METHODS: In this randomized controlled trial, 20 patients were randomized to HCR (n = 10) or HCR + RMT (n = 10). Rehabilitation started in postoperative week 1 and continued for 8 weeks. Both groups received HCR, while the HCR + RMT group performed combined inspiratory and expiratory muscle training. Primary outcomes were pulmonary function, respiratory muscle strength, and 6-min walk distance. Secondary outcomes included quality of life, physical activity, usability, feasibility, and satisfaction.
RESULTS: Twenty participants completed the study, with 100% retention and attendance in both groups and no adverse events. At postoperative week 1, respiratory and functional parameters declined in both groups. By week 8, 6-min walk distance increased by 49.5 m in the HCR group and 55.5 m in the HCR + RMT group. Duke Activity Status Index scores improved by 5.25 and 4.95 points, respectively, while Minnesota Living with Heart Failure Questionnaire scores decreased by 7-9 points. No significant between-group differences were found for any outcome (all p > 0.05).
CONCLUSIONS: Adding RMT to HCR is feasible, safe, and well accepted. Both interventions improved respiratory function, respiratory muscle strength, functional capacity, physical activity, and quality of life. Although no additional short-term benefit was observed with RMT, it may be considered complementary to HCR programs.
CLINICAL TRIAL REGISTRATION NUMBER: NCT06258681.
OBJECTIVE: To evaluate the effects of adding RMT to an HCR program following cardiac surgery in a randomized controlled trial.
METHODS: In this randomized controlled trial, 20 patients were randomized to HCR (n = 10) or HCR + RMT (n = 10). Rehabilitation started in postoperative week 1 and continued for 8 weeks. Both groups received HCR, while the HCR + RMT group performed combined inspiratory and expiratory muscle training. Primary outcomes were pulmonary function, respiratory muscle strength, and 6-min walk distance. Secondary outcomes included quality of life, physical activity, usability, feasibility, and satisfaction.
RESULTS: Twenty participants completed the study, with 100% retention and attendance in both groups and no adverse events. At postoperative week 1, respiratory and functional parameters declined in both groups. By week 8, 6-min walk distance increased by 49.5 m in the HCR group and 55.5 m in the HCR + RMT group. Duke Activity Status Index scores improved by 5.25 and 4.95 points, respectively, while Minnesota Living with Heart Failure Questionnaire scores decreased by 7-9 points. No significant between-group differences were found for any outcome (all p > 0.05).
CONCLUSIONS: Adding RMT to HCR is feasible, safe, and well accepted. Both interventions improved respiratory function, respiratory muscle strength, functional capacity, physical activity, and quality of life. Although no additional short-term benefit was observed with RMT, it may be considered complementary to HCR programs.
CLINICAL TRIAL REGISTRATION NUMBER: NCT06258681.